Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 30;66(25):668-676.
doi: 10.15585/mmwr.mm6625a3.

Update: Influenza Activity in the United States During the 2016-17 Season and Composition of the 2017-18 Influenza Vaccine

Lenee Blanton  1 , Noreen Alabi  1 , Desiree Mustaquim  1 , Calli Taylor  1 , Krista Kniss  1 , Natalie Kramer  1 , Alicia Budd  1 , Shikha Garg  1 , Charisse N Cummings  1 , Jessie Chung  1 , Brendan Flannery  1 , Alicia M Fry  1 , Wendy Sessions  1 , Rebecca Garten  1 , Xiyan Xu  1 , Anwar Isa Abd Elal  1 , Larisa Gubareva  1 , John Barnes  1 , Vivien Dugan  1 , David E Wentworth  1 , Erin Burns  1 , Jacqueline Katz  1 , Daniel Jernigan  1 , Lynnette Brammer  1
Affiliations

Update: Influenza Activity in the United States During the 2016-17 Season and Composition of the 2017-18 Influenza Vaccine

Lenee Blanton et al. MMWR Morb Mortal Wkly Rep. .

Abstract

During the 2016-17 influenza season (October 2, 2016-May 20, 2017) in the United States, influenza activity* was moderate. Activity remained low through November, increased during December, and peaked in February nationally, although there were regional differences in the timing of influenza activity. Influenza A(H3N2) viruses predominated through mid-March and were predominant overall for the season, but influenza B viruses were most commonly reported from late March through May. This report summarizes influenza activity in the United States during October 2, 2016-May 20, 2017† and updates the previous summary (1).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Jacquline Katz reports U.S. Patent 6,196,175 (issued 01/02/2001) and U.S. Patent 8,163,545 (issued 4/26/2012). No other conflicts of interest were reported.

Figures

FIGURE 1
FIGURE 1
Number and percentage of respiratory specimens testing positive for influenza reported by clinical laboratories, by influenza virus type and surveillance week — United States, October 2, 2016–May 20, 2017 * Specimens from 121,223 (14.0%) of 865,168 persons tested positive during October 2, 2016–May 20, 2017. † As of June 9, 2017.
FIGURE 2
FIGURE 2
Number of respiratory specimens testing positive for influenza reported by public health laboratories, by influenza virus type, subtype/lineage, and surveillance week — United States, October 2, 2016–May 20, 2017 * N = 40,728. † As of June 9, 2017.
FIGURE 3
FIGURE 3
Percentage of visits for influenza-like illness (ILI) reported to CDC, by surveillance week — Outpatient Influenza-Like Illness Surveillance Network, United States, 2016–17 influenza season and selected previous influenza seasons * Defined as fever (temperature ≥100.0°F [≥37.8°C], oral or equivalent) and cough and/or sore throat, without a known cause other than influenza. † As of June 9, 2017.
See this image and copyright information in PMC

References

    1. Blanton L, Mustaquim D, Alabi N, et al. Update: influenza activity United States, October 2, 2016–February 4, 2017. MMWR Morb Mortal Wkly Rep 2017;66:159–66. 10.15585/mmwr.mm6606a2 - DOI - PMC - PubMed
    1. Food and Drug Administration. Summary minutes: meeting of the Vaccines and Related Biological Products Advisory Committee. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2017. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateri...
    1. CDC. Disease burden of influenza. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/flu/about/disease/burden.htm
    1. Foppa IM, Cheng PY, Reynolds SB, et al. Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14. Vaccine 2015;33:3003–9. 10.1016/j.vaccine.2015.02.042 - DOI - PMC - PubMed
    1. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016;16:942–51. 10.1016/S1473-3099(16)00129-8 - DOI - PubMed

MeSH terms

Substances